Ordering, interpretation & the molecular tumour board.
A decision-ready report, ranked, evidenced, and co-signed.
OnKommon exists to give you back the two things comprehensive genomics too often costs you: time and certainty. We do the interpretive heavy lifting and deliver a decision-ready report — ranked, evidenced, and co-signed by a molecular tumour board — so you can act on your patient's biology without wading through raw variant tables. You remain the treating clinician; we are the intelligence and the second set of expert eyes behind you.
1 · What OnKommon gives the treating clinician
OnKommon exists to give you back the two things comprehensive genomics too often costs you: time and certainty. We do the interpretive heavy lifting and deliver a decision-ready report — ranked, evidenced, and co-signed by a molecular tumour board — so you can act on your patient's biology without wading through raw variant tables. You remain the treating clinician; we are the intelligence and the second set of expert eyes behind you.
2 · The decision, made faster
Every Blueprint Care report opens with a one-page Chief Oncologist Summary designed to be read in under a minute: the Actionability Index, the recommended first-line direction, explicit contraindications, and urgent flags (trial-ready, hereditary-risk referral). Beneath it sits the full evidence — variants tiered by AMP/ASCO/CAP, ESCAT, and OncoKB levels, with a concordance view so you can see where frameworks agree.
Ranked therapy options
Ranked therapy options with the rationale and evidence tier for each.
Explicit contraindications
Explicit contraindications — what this tumour will resist, stated plainly.
Matched clinical trials
Matched clinical trials for the exact molecular profile.
Biosimilar & access mapping
Biosimilar and access mapping for the Indian context.
Pharmacogenomics
Pharmacogenomics to dose safely and avoid severe adverse reactions.
3 · Time & workflow
We fit your workflow, not the other way around. Sample logistics (home or in-clinic phlebotomy, or an existing FFPE block) are handled for your patient. Turnaround is transparent and, for urgent cases, the focused Signature STb pathway is built for speed. Reports arrive in a consistent, skimmable structure every time.
4 · Accountability — the clean answer
Software informs. A clinician decides.
Every clinically consequential statement in an OnKommon report is authored and signed by a licensed molecular tumour board through KPCIRC. Our engine annotates, matches, and models — but it does not diagnose or prescribe, and it never has the final word. This is deliberate: it gives you a defensible, human-authored decision and a named clinical partner to discuss it with.
5 · Monitoring that closes the loop
Precision oncology does not end at the first decision. Sentinel gives you serial ctDNA monitoring to see response and catch resistance early; Clear provides tumour-informed MRD surveillance after curative-intent treatment. Both escalate findings back to you and the molecular tumour board, so you are never the last to know.
6 · Ordering & sample logistics
Five steps from referral to result.
Refer or order
Contact the clinician desk or order a Signature test; we advise on the right tier for the question.
Sample handled
Home/in-clinic phlebotomy for blood, or retrieval of an existing FFPE block — coordinated for your patient.
Sequencing & engine
Accredited sequencing, then interpretation through the OnKommon engine.
MTB sign-out
A molecular tumour board reviews, authors, and signs the report.
Report + discussion
You receive the report and can request a tumour board discussion or second opinion.
7 · Molecular tumour board & second opinions
Through KPCIRC you can access a molecular tumour board discussion of a specific case, or an independent second opinion — provided on a paid basis. This is the same authority that signs our reports, available to you directly when a case is complex or a family wants another expert view.
8 · Contribute to research
Ordering through OnKommon can, with appropriate consent, contribute de-identified clinicogenomic data to research that improves interpretation for the next patient — and connects your patients to biomarker-matched trials. Participation is optional and governed by strict consent and data-protection standards.
ACCREDITATION & METHODS
How your patient's result is produced
Transparency on provenance: sequencing and variant calling are performed by an accredited laboratory partner (CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP), using a CE-IVD certified variant database for classification and reporting. The OnKommon interpretation engine adds biomarker matching, modelling and the intelligence layers and is provided for research and decision-support use — it does not make a diagnosis. Every report discloses panel scope, per-gene coverage, tumour fraction and limitations.
CAP-Accredited
Sequencing and variant calling performed by a College of American Pathologists (CAP-accredited) laboratory.
ISO 15189
Laboratory partner holds ISO 15189 accreditation, meeting international quality standards.
Guideline-Aligned
Following ACMG/AMP/ASCO/CAP international guidelines, using a CE-IVD certified variant database.
RESEARCH & EVIDENCE
The science behind this
The OnKommon approach — comprehensive profiling reviewed by a molecular tumour board — rests on a substantial peer-reviewed evidence base.
Study 1 · MTB-guided matched therapy
Across 715 advanced-cancer patients, closer matching between therapy and the molecular profile on MTB advice was associated with improved response and survival.
Study 2 · Liquid-biopsy CGP is guideline-supported
NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue; ASCO recommends blood cfDNA as the specimen of choice for comprehensive profiling in advanced breast cancer.
Study 3 · Plasma genotyping increases matched therapy
Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.
These independent, peer-reviewed studies describe the class of technology OnKommon uses. They are shared for education; they are not results for any individual and are not a promise of benefit.
TRANSPARENCY — WHAT WE DO AND DON'T
Being clear about our limits
What we DO
- Deliver a ranked, evidence-tiered, MTB-signed report
- Grade variants against AMP/ASCO/CAP, ESCAT and OncoKB levels
- Flag contraindications, matched trials, biosimilars and PGx
- Offer serial monitoring and second-opinion MTB access
What we DON'T do
- Diagnose or prescribe — you retain clinical responsibility
- Claim autonomous, AI-only decision-making
- Guarantee drug availability, approval, cover or efficacy
- Replace confirmatory or companion diagnostic testing where required
DATA, CONSENT & GOVERNANCE
How patient data is handled
Patient data is encrypted and access-controlled and handled under India's Digital Personal Data Protection Act, 2023. Testing and any research use require explicit, informed consent, and de-identified data contributes to research only under a separate consent and an approved protocol. OnKommon's IVD registration with CDSCO is in progress; where a programme is investigational or research-stage, we say so.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
Need a second opinion or professional feedback?
If you want an independent clinical view — or you are a clinician seeking a molecular tumour board discussion — our exclusive clinical partner KPCIRC provides paid second opinions, molecular tumour board reviews, and genetic counselling. Ask your navigator, or request it from any page.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →